Clinical Trials

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT06097364 2026-02-06

OLYMPIA-2

733 enrolled

Phase 2 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT06253663 2025-12-16

JKART-1

25 enrolled

Phase 2 Active not recruiting

Recurrence, Lymphoma, Mantle-Cell

NCT04245839 2025-11-05

TRANSCEND FL

276 enrolled 2 FDA

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02625480 2025-09-29

ZUMA-4

95 enrolled

Recurrence, Lymphoma, B-Cell

NCT05883449 2025-08-20

LuminICE-203

Phase 2 Terminated

25 enrolled 21 charts

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT05972720 2025-05-15

FIRCE-1

Phase 2 Terminated

101 enrolled

Phase 3 Active not recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05578976 2025-01-23

EPCORE DLBCL-2

900 enrolled

Phase 2 Not yet recruiting

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06367114 2024-04-19

Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

50 enrolled

BreastGenitourinaryGynecologic

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03861403 2023-11-30

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Phase 1 Terminated

10 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence

NCT03624036 2023-11-18

ZUMA-8

Phase 1 Terminated

16 enrolled 17 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

45 enrolled

Multiple Myeloma, Recurrence

NCT04825496 2023-09-21

Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1 Unknown

18 enrolled

Phase 1 Active not recruiting

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04613557 2023-08-31

IMMUNICY-1

18 enrolled

Multiple Myeloma, Recurrence

NCT05727683 2023-02-14

CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia

Phase 1 Unknown

33 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04030195 2023-01-31

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Phase 1/2 Completed

18 enrolled 13 charts

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT03168438 2022-01-11

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Phase 1 Terminated

6 enrolled 19 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT04162756 2021-10-14

ZUMA-18

Approved for marketing

Phase EARLY_PHASE1 Unknown

Recurrence, Lymphoma, Mantle-Cell

NCT02785250 2021-06-18

Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Phase 1/2 Unknown

85 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasms, Recurrence

NCT04626752 2020-11-13

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

50 enrolled